Margetuximab in HER2-positive metastatic breast cancer

William J. Gradishar*, Ruth O'Regan, Mothaffar F. Rimawi, Jeffrey L. Nordstrom, Minori K. Rosales, Hope S. Rugo

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Several anti-HER2 agents are approved for third-line treatment and beyond (after first-line and second-line); however, no specific treatment strategy is recommended for third-line and beyond. Although these agents improve disease outcomes, HER2-positive metastatic breast cancer remains incurable and there is an unmet need for effective therapies in the later line setting. This review focuses on the development of margetuximab-cmkb, a novel, Fc-engineered, anti-HER2 monoclonal antibody, and its role in the systemic treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. Plain language summary - A new treatment option for patients with HER2-positive metastatic breast cancer In about 20% of patients with breast cancer, their tumor cells make too many copies of a protein called HER2. We call them HER2-positive breast cancer cells. HER2 is a protein that signals to breast cancer cells to make them grow. Certain drugs, known as antibodies, are able to bind to the HER2 proteins on the surface of the tumor cells. This stops their signaling and slows down the growth of the tumor cells. These antibodies are called anti-HER2 antibodies. In addition to its 'head' region binding to HER2, the 'tail' region of the anti-HER2 antibody can bind to certain other proteins (receptors) found on the surface of immune cells. When the anti-HER2 antibodies bind to the receptors on immune cells, this starts an anticancer immune response against the HER2-positive breast cancer cells and kills them. This review explains how anti-HER2 antibodies may block and destroy HER2-positive breast cancer cells. In particular, we focus on the beneficial and adverse effects of margetuximab, an anti-HER2 antibody. The tail region of margetuximab has been changed to boost the immune responses against HER2-positive cancer cells. Margetuximab is approved in the USA for patients with HER2-positive metastatic breast cancer after they have already received two or more anti-HER2 therapies. The decision to approve this was based on the pivotal clinical trial SOPHIA.

Original languageEnglish (US)
Pages (from-to)1099-1112
Number of pages14
JournalFuture Oncology
Issue number16
StatePublished - May 1 2023


  • Fc engineering
  • FcγRIIIA genotype
  • clinical trial
  • human epidermal growth factor receptor 2
  • margetuximab
  • metastatic breast cancer
  • monoclonal antibody

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Margetuximab in HER2-positive metastatic breast cancer'. Together they form a unique fingerprint.

Cite this